Chapter 3 · Moat
Robots, data,
and AI applied
to biology.
The intended moat is a compounding platform. Whether it compounds is the open question.
↓ scroll to read
✦ The bottom line
Ginkgo's would-be moat is its automated biofoundry (robots that run biological experiments at scale) plus the data it accumulates from every project — increasingly paired with AI. In theory, each project makes the platform smarter and cheaper, so it compounds. In practice, that flywheel hasn't yet shown up as growing revenue.
↓ the brief below
✦ Teach me
A moat that has to prove itself
The dream version of Ginkgo is like a cloud platform for biology: huge upfront investment in automation and data, then each new customer is cheaper to serve and the accumulated know-how is impossible to copy. That would be a deep moat.
The catch: a platform is only a moat if it actually attracts and retains paying demand. Ginkgo has the infrastructure and the data, but until customers and revenue grow on the back of it, the 'compounding flywheel' remains a thesis, not a proven moat.
Wall Street calls this
Platform / data flywheel
It's the crux of the whole investment: if the platform compounds, Ginkgo is undervalued infrastructure; if it doesn't, it's an expensive lab. The evidence so far (falling revenue) leans skeptical — which is why this is a high-risk bet, not a sure moat.